NCT03379051

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: TG Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Phase I/II Study of Venetoclax or Lenalidomide in Combination with Ublituximab and Umbralisib in Subjects with Relapsed or Refractory CLL/SLL and NHL

Conditions

• Chronic Lymphocytic Leukemia
• Non-Hodgkin Lymphoma

Interventions

Type	Name	Description
DRUG	Venetoclax	BCL-2 Inhibitor
DRUG	Umbralisib	PI3K-Delta Inhibitor
BIOLOGICAL	Ublituximab	Glycoengineered Anti-CD20 mAb
DRUG	Lenalidomide	Thalidomide Analog, immunomodulatory agent with antiangiogenic and antineoplastic properties

Timeline

• Start date: 2018-03-27
• Primary completion: 2022-05-26
• Completion: 2022-06-16
• First posted: 2017-12-20
• Last updated: 2022-08-22

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study